

Garrett M Dancik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3061797/publications.pdf>

Version: 2024-02-01

33
papers

1,190
citations

430874

18
h-index

434195

31
g-index

34
all docs

34
docs citations

34
times ranked

2633
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | <i>TERT</i> promoter mutations and telomerase reactivation in urothelial cancer. <i>Science</i> , 2015, 347, 1006-1010. | 12.6 | 255 |
| 2 | A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. <i>Lancet Oncology</i> , 2011, 12, 137-143. | 10.7 | 138 |
| 3 | Concurrent Alterations in <i>TERT</i> , <i>KDM6A</i> , and the BRCA Pathway in Bladder Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 4935-4948. | 7.0 | 101 |
| 4 | Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy. <i>Communications Biology</i> , 2020, 3, 720. | 4.4 | 82 |
| 5 | <i>shinyGEO</i> : a web-based application for analyzing gene expression omnibus datasets. <i>Bioinformatics</i> , 2016, 32, 3679-3681. | 4.1 | 64 |
| 6 | An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression. <i>Cancer Cell</i> , 2016, 30, 432-443. | 16.8 | 58 |
| 7 | Biomarkers for prognosis and treatment selection in advanced bladder cancer patients. <i>Current Opinion in Urology</i> , 2011, 21, 420-427. | 1.8 | 41 |
| 8 | A Cell of Origin Gene Signature Indicates Human Bladder Cancer Has Distinct Cellular Progenitors. <i>Stem Cells</i> , 2014, 32, 974-982. | 3.2 | 40 |
| 9 | Role in Tumor Growth of a Glycogen Debranching Enzyme Lost in Glycogen Storage Disease. <i>Journal of the National Cancer Institute</i> , 2014, 106, . | 6.3 | 38 |
| 10 | Parameter estimation and sensitivity analysis in an agent-based model of <i>Leishmania major</i> infection. <i>Journal of Theoretical Biology</i> , 2010, 262, 398-412. | 1.7 | 36 |
| 11 | Transcriptional Signatures of Ral GTPase Are Associated with Aggressive Clinicopathologic Characteristics in Human Cancer. <i>Cancer Research</i> , 2012, 72, 3480-3491. | 0.9 | 36 |
| 12 | GON4L Drives Cancer Growth through a YY1-Androgen Receptor-CD24 Axis. <i>Cancer Research</i> , 2016, 76, 5175-5185. | 0.9 | 36 |
| 13 | Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder Cancer. <i>Molecular Cancer Research</i> , 2018, 16, 69-77. | 3.4 | 33 |
| 14 | <i>mlegp</i> : statistical analysis for computer models of biological systems using R. <i>Bioinformatics</i> , 2008, 24, 1966-1967. | 4.1 | 29 |
| 15 | Robust Prognostic Gene Expression Signatures in Bladder Cancer and Lung Adenocarcinoma Depend on Cell Cycle Related Genes. <i>PLoS ONE</i> , 2014, 9, e85249. | 2.5 | 26 |
| 16 | Patient Mutation Directed shRNA Screen Uncovers Novel Bladder Tumor Growth Suppressors. <i>Molecular Cancer Research</i> , 2015, 13, 1306-1315. | 3.4 | 24 |
| 17 | A Framework to Select Clinically Relevant Cancer Cell Lines for Investigation by Establishing Their Molecular Similarity with Primary Human Cancers. <i>Cancer Research</i> , 2011, 71, 7398-7409. | 0.9 | 22 |
| 18 | Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis. <i>Cancer Research</i> , 2017, 77, 4858-4867. | 0.9 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | RhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer. <i>Molecular Cancer Research</i> , 2015, 13, 483-492. | 3.4 | 18 |
| 20 | Pharmacogenomics in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 16-22. | 1.6 | 15 |
| 21 | An online tool for evaluating diagnostic and prognostic gene expression biomarkers in bladder cancer. <i>BMC Urology</i> , 2015, 15, 59. | 1.4 | 14 |
| 22 | Genomic Heterogeneity and the Small Renal Mass. <i>Clinical Cancer Research</i> , 2018, 24, 4137-4144. | 7.0 | 11 |
| 23 | A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors. <i>PLOS Currents</i> , 2011, 3, RRN1248. | 1.4 | 11 |
| 24 | Glycogen debranching enzyme (AGL) is a novel regulator of non-small cell lung cancer growth. <i>Oncotarget</i> , 2018, 9, 16718-16730. | 1.8 | 10 |
| 25 | The Prognostic Value of Cell Cycle Gene Expression Signatures in Muscle Invasive, High-Grade Bladder Cancer. <i>Bladder Cancer</i> , 2015, 1, 45-63. | 0.4 | 7 |
| 26 | Lower RNA expression of ALDH1A1 distinguishes the favorable risk group in acute myeloid leukemia. <i>Molecular Biology Reports</i> , 2022, 49, 3321-3331. | 2.3 | 7 |
| 27 | The Cell Cycle Progression Score: Unclear Role in Renal Cell Carcinoma. <i>European Urology</i> , 2018, 74, 128-129. | 1.9 | 6 |
| 28 | Aldehyde Dehydrogenase Enzyme Functions in Acute Leukemia Stem Cells. <i>Frontiers in Bioscience - Scholar</i> , 2022, 14, 8. | 2.1 | 5 |
| 29 | Genomic case report of a low grade bladder tumor metastasis to lung. <i>BMC Urology</i> , 2018, 18, 74. | 1.4 | 3 |
| 30 | Elucidating the role of Agl in bladder carcinogenesis by generation and characterization of genetically engineered mice. <i>Carcinogenesis</i> , 2019, 40, 194-201. | 2.8 | 2 |
| 31 | Using Cell Lines To Guide Neoadjuvant Therapy in Bladder Cancer: COXEN and SWOG S1314. <i>European Urology Focus</i> , 2022, , . | 3.1 | 2 |
| 32 | Cancer Publication Portal: an online tool for summarizing and searching human cancer-genomic publications. <i>F1000Research</i> , 0, 8, 2073. | 1.6 | 1 |
| 33 | Personalized Medicine. , 2018, , 659-673. | | 0 |